Trial · NCT03168776
Results by group74
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 74
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | BuMA Supreme Coronary Stent System (ITT) | TLF | 5.4 | 95% Confidence Interval 4.1 to 6.9 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | Durable Polymer EES (XIENCE or Promus DES) (ITT) | TLF | 5.1 | 95% Confidence Interval 3.4 to 7.3 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | BuMA Supreme Coronary Stent System (ITT) | Cardiac Death | 0.3 | 95% Confidence Interval 0.1 to 0.8 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | Durable Polymer EES (XIENCE or Promus DES) (ITT) | Cardiac Death | 0.8 | 95% Confidence Interval 0.2 to 1.9 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | BuMA Supreme Coronary Stent System (ITT) | Target vessel MI | 3.4 | 95% Confidence Interval 2.4 to 4.7 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | Durable Polymer EES (XIENCE or Promus DES) (ITT) | Target vessel MI | 4.2 | 95% Confidence Interval 2.6 to 6.2 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | BuMA Supreme Coronary Stent System (ITT) | Clinically Driven TLR | 2.3 | 95% Confidence Interval 1.5 to 3.4 | percentage of subjects with TLF |
| Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements | Durable Polymer EES (XIENCE or Promus DES) (ITT) | Clinically Driven TLR | 0.9 | 95% Confidence Interval 0.3 to 2.2 | percentage of subjects with TLF |
| Number of Participants With Cardiac Death | BuMA Supreme Coronary Stent System (ITT) | 30 Days | 2 | Participants | |
| Number of Participants With Cardiac Death | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 30 Days | 1 | Participants | |
| Number of Participants With Cardiac Death | BuMA Supreme Coronary Stent System (ITT) | 6 Months | 3 | Participants | |
| Number of Participants With Cardiac Death | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 6 Months | 3 | Participants | |
| Number of Participants With Cardiac Death | BuMA Supreme Coronary Stent System (ITT) | 12 Months | 3 | Participants | |
| Number of Participants With Cardiac Death | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 12 Months | 4 | Participants | |
| Number of Participants With Cardiac Death | BuMA Supreme Coronary Stent System (ITT) | 5 Years | 25 | Participants | |
| Number of Participants With Cardiac Death | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 5 Years | 16 | Participants | |
| Number of Participants With Major Adverse Cardiac Events (MACE) | BuMA Supreme Coronary Stent System (ITT) | 30 Days | 39 | Participants | |
| Number of Participants With Major Adverse Cardiac Events (MACE) | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 30 Days | 22 | Participants | |
| Number of Participants With Major Adverse Cardiac Events (MACE) | BuMA Supreme Coronary Stent System (ITT) | 6 Months | 58 | Participants | |
| Number of Participants With Major Adverse Cardiac Events (MACE) | Durable Polymer EES (XIENCE or Promus DES) (ITT) | 6 Months | 33 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03168776/results